Celsion Corporation  

(Public, NASDAQ:CLSN)   Watch this stock  
Find more results for CLSN
2.89
-0.05 (-1.70%)
Feb 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.88 - 2.96
52 week 2.15 - 4.03
Open 2.95
Vol / Avg. 90,709.00/320,568.00
Mkt cap 57.73M
P/E     -
Div/yield     -
EPS -1.27
Shares 19.98M
Beta 1.77
Inst. own 21%

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -5553.88% -1650.27%
Operating margin -5335.03% -3082.30%
EBITD margin - -3014.45%
Return on average assets -36.36% -23.23%
Return on average equity -66.08% -59.11%
Employees 13 -
CDP Score - -

Address

Suite 100, 997 Lenox Drive
LAWRENCEVILLE, NJ 08648
United States - Map
+1-609-8969100 (Phone)
+1-609-8962200 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Celsion Corporation is an oncology drug development company. The company is focused on developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. Its lead program is ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer. Its pipeline also includes EGEN-001, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. The Company has three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas and TheraSilence.

Officers and directors

Jeffrey W. Church CPA Chief Financial Officer, Senior Vice President - Corporate Strategy and Investor Relations
Age: 57
Bio & Compensation  - Reuters
Khursheed Anwer Ph.D. Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy
Age: 55
Bio & Compensation  - Reuters
Nicholas Borys M.D. Vice President, Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
Michael H. Tardugno Executive Chairman of the Board, President, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
Pok Yu Chow Ph.D. Independent Director
Bio & Compensation  - Reuters
Frederick J. Fritz Independent Director
Age: 63
Bio & Compensation  - Reuters
Robert W. Hooper Independent Director
Age: 67
Bio & Compensation  - Reuters
Alberto R. Martinez M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters